Topics

TOPICS

ANEMIA

FDA Requests Clarification of Data to Complete Roxadustat Review

BCL11A Inhibition to Induce Fetal Hemoglobin Shows Promise in Sickle Cell Disease

BLEEDING DISORDERS

Dexamethasone May Not Improve Outcomes in Chronic Subdural Hematoma

Fibrinogen Concentrate for Bleeding Episodes in Pediatric Congenital Fibrinogen Deficiency

GENERAL HEMATOLOGY

Two Billion COVID-19 Vaccine Doses From BioNTech Expected This Year

Red Cross Issues Call for More Blood Plasma to Treat COVID-19 Patients

LEUKEMIA

Combination Sitagliptin, Tacrolimus, Sirolimus for Prophylaxis of Acute Graft-vs-Host-Disease

Reduced-Intensity Conditioning May Not Improve Post Allogeneic HSCT Outcomes in AML

LYMPHOMA

Burkitt Lymphoma: Clinical, Pathologic, and Genomic Features in Adults

Risk Factors for Early Relapse of DLBCL After CAR-T Therapy

MYELODYSPLASTIC SYNDROMES

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML

Greater KIAA0125 Expression Is Poor Prognostic Factor for Myelodysplastic Syndrome

MYELOMA

Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma

Laboratory Markers Found to Correlate With Symptom Burden in Relapsed/Refractory Multiple Myeloma

SIDE EFFECT MANAGEMENT

ONS Releases Guidelines on the Management of Cancer Treatment–Related Hot Flashes

New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects

THALASSEMIAS

CRISPR-Cas9 Gene Editing May Be Effective in β-Thalassemia, Sickle Cell Disease

Comorbidity Rate Remains High in Transfusion-Dependent β-Thalassemia Compared With General Population

THROMBOTIC DISORDERS

Current Treatment Options for Pregnancy-Related Venous Thromboembolism

Rivaroxaban vs Standard Anticoagulants for Pediatric Cerebral Venous Thrombosis

Next post in Leukemia

This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers.

Reduced-Intensity Conditioning May Not Improve Post Allogeneic HSCT Outcomes in AML